ReviewNature reviews. Nephrology2024
Vascular damage in systemic lupus erythematosus.
Review in Nature reviews. Nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Galectin-3 in systemic lupus erythematosus: a meta-analysis.Immunologic research · 2026Pooled it
- Statin therapy in systemic lupus erythematosus: a meta-analysis of disease activity and inflammatory biomarkers.Lupus science & medicine · 2026Pooled it
- Engineering bioactive citrate-based hydrogels for wound repair: From structure-function design to microenvironmental regulation.Bioactive materials · 2027Review
- Low-density granulocyte-driven NET formation is associated with poor prognosis in IgA nephropathy with thrombotic microangiopathy.Renal failure · 2026Article
- Persistent symptom burden in long-standing systemic lupus erythematosus: a subgroup-focused hypothesis for an SLE-ME/CFS research phenotype.Journal of translational medicine · 2026Article
- Review
- Anti-endothelin receptor A autoantibodies associate with immunovascular risk and activate endothelial signalling in SLE.Lupus science & medicine · 2026Article
- Risk of chronic kidney disease in newly diagnosed SLE with preserved renal function: a national study.Rheumatology (Oxford, England) · 2026Article
- Photoacoustic imaging of oxygen saturation in the radial arterial wall and perivascular tissue in patients with systemic lupus erythematosus.BMC medical imaging · 2026Article
- Autoimmune Disorders and Thrombophilia in Pathologic Pregnancies: Management Throughout the Full Gestation.Biomedicines · 2026Article
- Optic nerve head microcirculation on optical coherence tomography angiography is reduced in systemic lupus erythematosus and relates to nailfold videocapillaroscopy phenotypes: a cross-sectional case-control study.Clinical rheumatology · 2026Article
- Redefining Difficult-to-Treat Systemic Lupus Erythematosus: Biomarkers of Molecular Refractoriness Beyond Clinical Failure.International journal of molecular sciences · 2026Review
- Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration.Chinese medicine · 2026Review
- Neutrophil reprogramming underlie vasculopathy and lung disease in systemic sclerosis.Cell death & disease · 2026Article
- Plasma exosomal fibroblast activation protein: a novel biomarker links fatty acid metabolic dysregulation to systemic lupus erythematosus.Arthritis research & therapy · 2026Article
- Left Ventricular Mass Index as an independent predictor of major adverse cardiovascular and cerebrovascular events in patients with SLE.Lupus science & medicine · 2026Article
- Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.Lupus science & medicine · 2026Article
- The shared genetic architecture underlying the autoimmune and cardiovascular disease: a multivariate genome-wide analysis.Cardiovascular diabetology · 2026Article
- Article
- Neutrophil extracellular traps and acute kidney injury: a narrative review.Frontiers in immunology · 2026Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vascular disease is a major cause of morbidity and mortality in patients with systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE). Although comorbid cardiovascular risk factors are frequently present in patients with SLE, they do not explain the high burden of premature vascular disease. Profound innate and adaptive immune dysregulation seems to be the primary driver of accelerated vascular damage in SLE. In particular, evidence suggests that dysregulation of type 1 interferon (IFN-I) and aberrant neutrophils have key roles in the pathogenesis of vascular damage. IFN-I promotes endothelial dysfunction directly via effects on endothelial cells and indirectly via priming of immune cells that contribute to vascular damage. SLE neutrophils are vasculopathic in part because of their increased ability to form immunostimulatory neutrophil extracellular traps. Despite improvements in clinical care, cardiovascular disease remains the leading cause of mortality among patients with SLE, and treatments that improve vascular outcomes are urgently needed. Improved understanding of the mechanisms of vascular injury in inflammatory conditions such as SLE could also have implications for common cardiovascular diseases, such as atherosclerosis and hypertension, and may ultimately lead to personalized therapeutic approaches to the prevention and treatment of this potentially fatal complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.